Populations across the world are realizing that psilocybin and synthetic psychedelics can help alleviate severe depression and end-of-life distress, among many other palliative and non-palliative conditions.
Optimi is the leader of Safe Supply in Canada. Our facility produces the purest natural and synthetic pharmaceutical-grade investigational drugs to authorized patients and physicians in Canada with Section 56 Exemptions or permission under the Special Access Program (SAP). We also supply eligible academic researchers and clinical trials advancing the interest and understanding of psychedelic science as an innovative medical component to alleviate mental suffering.
Risks of not having Safe Supply:
Optimi produces the safest, most consistent, and purest natural psilocybin mushrooms available to authorized patients and physicians with Section 56 Exemptions or permission under the Special Access Program. We ensure quality to patients seeking therapeutic relief under the gradually-expanding prescription models for psilocybin.
Studies from leading institutions are establishing the efficacy of psilocybin as an alternative treatment for various mental health disorders. The US Food and Drug Administration has granted a Breakthrough Therapy designation to psilocybin.
Health Canada has come forward in support of the ongoing research, but recognizes the lack of studies using natural psilocybin and psilocin. Further progress is possible only with GMP-standardized natural psilocybin.
Optimi is working with Health Canada to provide that research using safe and standardized doses of natural psilocybin.
Optimi’s commercial facility can provide up to 5000 kilograms of dried psilocybin mushrooms, capable of producing 10 kilograms of psilocybin and 100 grams of psilocin at the highest operational standards of safety and quality, to supply authorized private and public sector researchers.
Get updates directly to your inbox.
Optimi Health Corp.
21 Water St #600, Vancouver, BC V6B 1A1
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Products do not contain psilocybin